Imagine detecting a single trillionth of a gram of a molecule—like an amino acid—using just electricity and a chip smaller than your fingernail. That’s the power of a new quantum-enabled biosensor developed at EPFL. Ditching bulky lasers, it taps into the strange world of quantum tunneling, where electrons sneak through barriers and release light in the process. MORE
197 
Science Daily: Pharmacology News
JULY 5, 2025
Scientists at the University of Sydney have uncovered a malfunctioning version of the SOD1 protein that clumps inside brain cells and fuels Parkinson’s disease. In mouse models, restoring the protein’s function with a targeted copper supplement dramatically rescued movement, hinting at a future therapy that could slow or halt the disease in people.
Chemical Biology and Drug Design
JULY 3, 2025
Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities. Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy. ABSTRACT The development of novel therapeutic drugs with enhanced efficacy has gained significant attention in recent years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Science Daily: Pharmacology News
JULY 2, 2025
A cutting-edge gene therapy has significantly restored hearing in children and adults with congenital deafness, showing dramatic results just one month after a single injection. Researchers used a virus to deliver a healthy copy of the OTOF gene into the inner ear, improving auditory function across all ten participants in the study. The therapy worked best in young children but still benefited adults, with one 7-year-old girl regaining almost full hearing.
BioPharma Drive: Drug Pricing
JULY 2, 2025
Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drugs.com
JULY 2, 2025
WEDNESDAY, July 2, 2025 -- The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain formulations of amphetamine and methylphenidate, to warn.
Drug Target Review
JULY 1, 2025
Clinical trials are expensive, slow and often limited by outdated design constraints. Placebo arms, in particular, create ethical and logistical hurdles, especially in areas like rare disease and oncology. Digital twins offer a way forward. They offer patient-specific outcome predictions, generated using machine learning models trained on real historical clinical data.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
BioPharma Drive: Drug Pricing
JULY 1, 2025
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.
Drugs.com
JULY 1, 2025
TUESDAY, July 1, 2025 — Opioid addicts covered by Medicare and Medicaid are less likely to receive the mental health and substance use treatment that they need, a new study says. Addicts with public insurance receive more than twice as many.
Chemical Biology and Drug Design
JULY 1, 2025
Two compounds, A16 and A17, were active against multidrug-resistant Mycobacterium tuberculosis isolates (PT-12 and PT-20), overcoming key resistance mutations in katG and rpoB, while cytotoxicity assays confirmed that they are non-toxic. A17 exhibited the highest antituberculosis activity, with molecular docking suggesting enoyl-[acyl-carrier-protein] reductase as a potential biological target.
Drug Target Review
JULY 3, 2025
It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. However, R&D stakeholders are learning that GenAI underpinned by domain expertise also enables deep dives into the broader long-term potential of their investigational asset(s) as early as the preclinical phase.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Science Daily: Pharmacology News
JULY 1, 2025
Researchers reviewing nearly 300 top-tier ADHD drug trials found that half skipped the rigorous, expert-led evaluations needed to rule out other conditions like depression or schizophrenia. With diagnoses often made by unqualified staff—or even by computer—many participants may not have actually had ADHD, casting doubt on study outcomes that shape treatment guidelines.
BioPharma Drive: Drug Pricing
JULY 1, 2025
Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray into pivotal testing.
Drugs.com
JULY 1, 2025
MONDAY, July 1, 2025 — The COVID-19 pandemic took a toll on Americans’ guts, researchers report. Gut disorders like irritable bowel syndrome (IBS) increased significantly during the COVID-19 pandemic, a new study says. Rates of IBS.
Chemical Biology and Drug Design
JULY 1, 2025
Determination of binding ability of flavonoids/phenolic acids to HSA by affinity capillary electrophoresis and fluorescence spectroscopy. ABSTRACT The interaction of small molecule drugs with human serum albumin (HSA) after entering the human blood circulation system profoundly affects their distribution and absorption in the body, and further influences the activity.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
New Drug Approvals
JULY 5, 2025
PALAZESTRANT CAS 2092925-89-6 OP-1250, VU35KM56Q4 449.6 g/mol, C 28 H 36 FN 3 O (1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3- yl)oxy]phenyl}-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Palazestrant (OP-1250) is an investigationa
Science Daily: Pharmacology News
JULY 2, 2025
Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers than our primate cousins. The change affects a protein used by immune cells to kill tumors—except in humans, it’s vulnerable to being shut down by an enzyme that tumors release. This flaw may be one reason treatments like CAR-T don’t work as well on solid tumors.
BioPharma Drive: Drug Pricing
JULY 2, 2025
Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.
Drugs.com
JULY 2, 2025
WEDNESDAY, July 2, 2025 — Having bad dreams after eating ice cream or cheese? Your stomach may be trying to tell you something. New research shows that people with worse symptoms of lactose intolerance tended to report more frequent.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Crown Bioscience
JULY 1, 2025
Highly targeted antibody-drug conjugates (ADCs) combine an antibody with a cytotoxic payload, covalently attached via a chemical linker. These “ biological missiles ” represent an exciting new advance in anti-cancer therapies and are one of the fastest-growing segments in oncology drug development. Due to their complex make-up and multiple components, analysis of their chemistry and functionality is challenging, requiring advanced assays and techniques for effective study and characterization.
SugarCone Biotech
JULY 6, 2025
A post-ASCO update on tumor targets DLL3, B7H3 and HER3 July 2025 Paul D Rennert, SugarCone Biotech LLC Introduction: DLL3, B7H3 and HER3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed.
Science Daily: Pharmacology News
JULY 2, 2025
Macquarie University researchers reveal that chlorothalonil, still commonly sprayed on American and Australian produce, cripples insect fertility by more than a third at residue levels typically found on food. The unexpectedly sharp drop in fruit-fly egg production suggests cascading damage to pollinator populations vital for crops and ecosystems. Although the fungicide is outlawed in the EU, Australian growers often apply it preventively, underscoring regulatory blind spots.
BioPharma Drive: Drug Pricing
JULY 7, 2025
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drugs.com
JULY 3, 2025
THURSDAY, July 3, 2025 -- There has been nationwide total of 1,267 confirmed cases of measles this year, with Kentucky being the latest state to announce an outbreak, the U.S. Centers for Disease Control and Prevention reported Wednesday.There are.
Drug Target Review
JULY 7, 2025
Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Their unique suitability has made them valuable for evaluating pharmacokinetics, toxicology and safety in drug candidates before human clinical trials.
Molecular Design
JULY 6, 2025
Here’s a photo from one of my exercise walks in Paramin and you can see the Caribbean Sea in the distance. This is perhaps my favourite view on the walk because it means that I’ve just got to the top of a particularly brutal hill (cars sometimes struggle to get to the top and on one occasion I watched a car fail miserably in four attempts) although you can’t always see the sea as clearly as in this photo.
BioPharma Drive: Drug Pricing
JULY 7, 2025
One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a competitor to Blueprint Medicines’ Ayvakit.
Drugs.com
JULY 3, 2025
THURSDAY, July 3, 2025 — There are three common health emergencies for which all U.S. schools should be prepared, a new study says. Brain-related crises like seizures, psychiatric conditions or substance abuse, and trauma-related injuries are.
Quanticate
JULY 3, 2025
Imagine being asked to join a clinical trial, but the nearest site is two hours away and you care for an elderly parent while working full-time. The burden of travel alone could be enough to say no. That’s the challenge decentralised clinical trials (DCTs) aim to solve.
Crown Bioscience
JULY 3, 2025
Often referred to as “magic bullets” or “biological missiles”, antibody-drug conjugates (ADCs) are one of the most promising advances in targeted cancer therapy, as they allow potent anti-cancer agents to be selectively delivered to cancer cells, while minimizing damage to healthy cells. This unique class of hybrid drugs typically contain a monoclonal antibody (mAbs) and a cytotoxic drug, attached via a chemical linker, combining “ both the advantages of highly specific targeting ability and hig
Science Daily: Pharmacology News
JULY 6, 2025
Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over 12 months, whereas placebo patients worsened. Those with high-risk genes even saw cognitive gains, hinting at real disease-modifying power.
BioPharma Drive: Drug Pricing
JULY 7, 2025
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less frequent dosing.
Drugs.com
JULY 3, 2025
THURSDAY, July 3, 2025 — The age-old “early to bed, early to rise” proverb applies to your daily exercise regimen as well as your health, wealth and wisdom, a new study says. Folks who get to bed earlier tend to be more physically.
Science Daily: Pharmacology News
JUNE 26, 2025
Imagine detecting a single trillionth of a gram of a molecule—like an amino acid—using just electricity and a chip smaller than your fingernail. That’s the power of a new quantum-enabled biosensor developed at EPFL. Ditching bulky lasers, it taps into the strange world of quantum tunneling, where electrons sneak through barriers and release light in the process.
Expert insights. Personalized for you.
Let's personalize your content